18-Jul-14 9:15 AM  CST

Tramadol Will Be A Schedule IV Drug

The Drug Enforcement Agency (DEA) has published its final rule in the Federal Register making Tramadol a Schedule IV Drug effective August 18th, 2014, according to the National Association Of State Controlled Substance Authorities (NASCSA). This is according to the Controlled Substance Act effective also on August 18th.  NASCSA also reports that Tramadol is already a controlled substance in Arkansas, Mississippi, and New York.

            With the August 18th deadline approaching, all manufacturers of Tramadol will be required to print “C-IV” on each and every bottle of the medication. Pharmacy technicians should make note of this change. Commercial bottles of Tramadol will not be able to be distributed without the new schedule IV designation and all DEA registrants will need to take a full inventory of all Tramadol stock in compliance with DEA rules and regulations.

            Tramadol is a narcotic-like pain reliever and is used to treat severe to moderate pain. Common side effects of Tramadol are headache, dizziness, drowsiness, tired feeling, constipation, diarrhea, nausea, vomiting, stomach pain, nervous or anxious feeling, itching, sweating, flushing, warmth, redness, or a tingly sensation may occur.

            It will remain to be seen whether changing the schedule of Tramadol will be beneficial in cutting down on substance abuse.






1. National Association of State Controlled Substances Authorities Press Release. “DEA Publishes Final Rules Rescheduling Tramadol to Schedule IV.” NASCSA. Web. Date of Access: 14 July 2014. 

2.  Awad, Nadia. “Now What?  DEA Tosses Tramadol In Schedule IV.” MedPage Today. Web.  Date of Access: 14 July 2014. 

For additional information on this article, please contact:
Source: Jennifer S. O’Reilly  

Tendenci™ User Home © 2004 Tendenci™ software by Schipul - "The Web Marketing Company" | www.schipul.com